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Abstract
Use of Antidepressant Medications and the Subsequent Course of Depressive
Symptoms among Older Adults
Janet Abou, Thomas Gill, Lisa Barry. Yale University School of Medicine-New Haven,
CT
Antidepressant medications are commonly prescribed for older adults with
depressive symptoms who may not have a major depressive disorder. Yet, the effect of
antidepressants on depressive symptoms over time in this population is largely unknown.
We sought to determine whether the use of antidepressant medications is
associated with a reduction in the severity of depressive symptoms over time.
Participants included 754 community-dwelling adults, aged 70+ years, who were
followed at 18-month intervals for 90 months. Depressive symptoms were assessed using
the 11-item CESD scale, with a higher score indicating worse depressive symptoms. A
linear mixed effects model, adjusted for demographic features, number of chronic
conditions, cognitive status, and physical frailty, was used to evaluate the effect of
antidepressant use on change in depressive symptoms score over time. In addition, among
persons with clinically significant depressive symptoms (i.e., CESD score >=20), we
evaluated whether antidepressant use was associated with a transition to a non-depressed
state (CESD score <20) using a Generalized Estimating Equations (GEE) model.
At baseline, participants taking an antidepressant (n=75) had higher mean CESD
scores than those not taking an antidepressant (15.1+ 9.2 vs. 8.5+8.3; p<0.001) and were
more likely to be female (p<0.001). Average unadjusted CESD change scores ranged
from -3.4 to 1.7 and 0.4 to 1.5 among those taking, and not taking, an antidepressant,
respectively (for the different 18-month intervals). Adjusted CESD scores worsened, on
average, for participants taking an antidepressant as compared with those not taking an

antidepressant. These differences were statistically significant between baseline to 18
months (p=0.03), 36 to 54 months (p=0.02) and 72 to 90 months (p=0.01). The
longitudinal findings indicated that CESD scores worsened by 2.2 points, on average,
among participants taking an antidepressant as compared with those not taking an
antidepressant, although this difference was not statistically significant (p=0.14). Among
participants with clinically significant depressive symptoms, use of antidepressants was
not associated with transitioning to a non-depressed state (OR=0.85, 95% CI 0.5-1.4).
Our findings raise concerns about the effectiveness of antidepressant medications,
as prescribed in clinical practice. Additional research is needed to better understand the
real world use and benefit of antidepressants among older adults.
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1. Background
1.1. Depression in Older Adults
Major depression, as defined by the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV), affects 1-2% of community-dwelling older adults.1 However, 618% of older adults experience clinically significant depressive symptoms that do not
meet the DSM-IV criteria for major depression.2-6 These clinically significant depressive
symptoms are commonly referred to in the literature as elevated depressive symptoms or
subthreshold depression, or subsyndromal depression.7-11

A number of longitudinal

studies have found that depressive symptoms are associated with worse health outcomes
in older adults. For example, elevated depressive symptoms have been shown to be
associated with increased mortality12, 13 and comorbid conditions such as coronary heart
disease14 and type 2 diabetes.15,

16

Depressive symptoms also have been found to be

associated with decreased cognition, disability in activities of daily living, and decreased
activity.14, 15, 17-19 The risk for major depressive disorder and suicide also increases among
older adults with elevated depressive symptoms.11,

20

Furthermore, greater healthcare

costs are accrued by older adults with elevated depressive symptoms.21-23 Despite the
public health significance of elevated depressive symptoms among older adults, however,
this condition is still widely underrecognized and undertreated.

1.2. Classification of Depression
Depressive disorders are classified in many ways. Clinically relevant depressive
disorders are defined by the DSM-IV and there are 3 main categories for depression 1)
Major depression, 2) Dysthymia and finally 3) Minor depression. Major depression as
defined by the DSM-IV as five (or more) of the following symptoms present during the
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same 2-week period and represent a change from previous functioning; at least one of the
symptoms is either depressed mood or anhedonia; 1) depressed mood, 2) anhedonia, 3)
significant weight loss when not dieting or weight gain, 4) insomnia or hypersomnia
nearly every day, 5) psychomotor agitation or retardation, 6) fatigue or loss of energy
nearly every day, 7) feelings of worthlessness or excessive or inappropriate guilt, 8)
decreased concentration, 9) recurrent thoughts of death. Dysthymia is characterized by
an overwhelming yet chronic state of depression, exhibited by a depressed mood for most
of the days, for more days than not, for at least 2 years. The symptoms are the same as
those described for major depression. Elevated depressive symptoms is not a clinical
diagnosis however it is made using screening tools for depression. The literature will
occasionally refer to elevated depressive symptoms as depression or minor depression
since the screening tools used are sensitive for detecting depression. However, without a
DSM diagnosis we will refrain from assigning a clinical diagnosis to elevated depressive
symptoms.

1.3. Underdiagnosis and Undertreatment of Depressive Symptoms
1.3.1. Underdiagnosis
Research suggests that major depression and elevated depressive symptoms in
older adults are more likely to be diagnosed and treated by primary care physicians than
by other specialists, such as psychiatrists.24 It also has been indicated that older adults
prefer to be treated by their primary care physician for problems related to mental
health.25 However, depression in older adults is frequently underdiagnosed and
undertreated in the primary care setting.26
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Patient-related factors may contribute to the underdiagnosis and undertreatment of
depression in this population. Patients’ fear of stigmatization of having depression,
discomfort with medical treatment, belief that depression is part of normal aging,
physical illness, and grief may delay or prevent older adults from seeking antidepressant
treatment.27,

28 29-31

Givens et al.32 conducted a qualitative study and found that older

adults resisted antidepressant treatment due to four main reasons; 1) fear of addiction, 2)
not viewing depression as a medical disease, 3) reluctance to prevent natural sadness, and
4) poor experience with prior medication. It is also possible that impairments in patients’
vision, hearing or cognitive function might delay physicians’ ability to recognize and
diagnose depression because these impairments affect communication between the
patient and physician.33,

34

In addition, older adults are more likely to give socially

desirable responses to physicians’ inquiries about mood as compared with younger
adults,33,

35

thereby making it more difficult for physicians’ to detect the presence of

depressive symptoms.
Several physician factors also have been shown to contribute to the
underdiagnosis and undertreatment of depression in older adults.

Physicians may

mistakenly think that persistent depressive symptoms are an acceptable response to
aging-related illnesses or conditions.36 For example, symptoms of depression are often
mistaken for irreversible dementia.37 Similarly, depression may be incorrectly considered
as an inevitable response to loss of social support/socialization38

39

and to financial

hardships that often accompany aging, rather than to a potentially treatable and reversible
condition.1 Lack of confidence when diagnosing and treating depression among older
adults also may contribute to the underrecognition and undertreatment of depression. In

4
one study of 153 internists, only 55% and 35% felt confident diagnosing and treating
depression, respectively, among their older adult patients.40 Another potential problem is
that physicians do not have enough time to establish rapport and to interview patients
regarding nonmedical life issues, which could provide insight into distinguishing
depression from other medical illnesses.40
Detection of depression can be accomplished through several formal screening
tools available for use in older adults. These include the Center for Epidemiologic Study
Depression Scale (CESD), Geriatric Depression Scale (GDS), or two simple questions
about mood and anhedonia ("Over the past 2 weeks, have you felt down, depressed, or
hopeless?" and "Over the past 2 weeks, have you felt little interest or pleasure in doing
things?").41-43 Evidence suggests that administration of a screening tool can improve
recognition of depression in older persons. One study, in an emergency department
setting, found that use of a screening tool such as the GDS identified 60% more cases of
depression than physicians’ assessments alone.44 However, despite these prior findings
and a recommendation by the U.S. Preventive Services Task Force (USPSTF) to screen
adults for depression,45 less than a third of physicians use a systematic screening device to
evaluate depressive symptoms.46 Consequently, there is ample opportunity to improve
primary care physicians’ recognition of depressive symptoms in older adults.

1.3.2. Undertreatment
Even when depressive symptoms are diagnosed in older adults, failure to treat
depressive symptoms is common.24 Luber et al. found that only one-third of the older
outpatients who were diagnosed as depressed by their primary care providers received
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antidepressant treatment.30 In a study conducted in London, these investigators found
that only 38% of patients mentioned their symptoms to their primary care physician; and
of those found to have elevated depressive symptoms, only 14% were prescribed an
antidepressant, while 24% were prescribed a hypnotic.47 In a study by Callahan et al.48,
less than half of older adults identified as having depressive symptoms received
antidepressant treatment.

1.4. Rates of Antidepressant Use Among Older Adults
Among older adults who are treated for depressive symptoms, antidepressants are
the most common form of treatment. In a survey of 215 physicians, many physicians
were uncertain about the benefits of psychotherapy for older persons. For example, only
57% thought that psychotherapy was as effective in older adults as it is in younger
persons.49 According to a cross-sectional study, only 1% of older adults have visited a
psychotherapist.50

A meta-analysis evaluating the efficacy of cognitive behavioral

therapy (CBT) in older adults found that it was efficacious when compared to those
waitlisted for psychotherapy.51
When antidepressants were first introduced, the first line therapies were Tricyclic
Antidepressants (TCA’s).

However, side effects from these medications can be of

concern in older adults because they can cause difficulties with memory and dizziness,
and they increase the risk of falls.52 Selective serotonin reuptake inhibitors (SSRI’s) are
now considered the first line therapy for depression and depressive symptoms in older
adults as they have been shown to have fewer side effects and are better tolerated than
TCAs.52 In 1993, 9.6% of the antidepressants prescribed were SSRI’s, while in 1997,
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45.1% of the antidepressants prescribed were SSRI’s, as determined through prescribing
records for all adults.53, 54
Antidepressant prescribing and use has increased modestly in older adults during
the last decade. The rate of antidepressant use in older adults, regardless of depression
status, between the 1980’s and the early 1990’s ranged from 2.3% to 9.3%.53, 55 In the late
1990’s through the present, the rate of antidepressant use in older adults ranged from
8.1% to 11.5%.53,55, 56 The increased use of antidepressants in the past decade is attributed
to the availability of the SSRI’s and increased knowledge and familiarity with these
medications by prescribing physicians.57 Nonetheless, even with the wider availability of
SSRI’s, older adults continue to be undertreated.58

1.5. Effectiveness of Antidepressants
1.5.1. Clinical Trials in Specialized Populations
Although antidepressant medication is the most common form of treatment for
depression in older adults, relatively little is known about whether pharmacologic
treatment improves depressive symptoms that do not meet DSM-IV criteria for
depression, dysthymia or minor depression in this population. As will be discussed, most
of what we know regarding the effectiveness of antidepressants in older adults comes
from clinical trials, many of which have included mixed-age samples (i.e., participants <
65 years and ≥65 years), and specialized populations, such as patients who are
institutionalized or being treated by a psychiatrist rather then a primary care provider,
The results from such trials may not be generalizable to the population of depressed older
adults who are commonly seen in clinical practice.
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In 1997, a consensus statement was released regarding both pharmacological and
non-pharmacological treatment of depression in late-life which stressed that there were
effective treatments for depression and that aggressive approaches to diagnosis (i.e.
routine screening followed by diagnostic testing for patients that have elevated depressive
symptoms) and treatment (i.e. treatment for a long duration and medication at
recommended doses) are warranted.1 In 1999, a subsequent consensus statement was
released that drew attention to the relative paucity of mental health care for the geriatric
population and the need for increased research.59 In preparation for the 2002 consensus
statement on the treatment of depression in late-life, Salzman et al. evaluated clinical
trials of antidepressant treatment in adults, aged 65 years or older. These investigators
found that there has been an increase in the number of clinical trials evaluating the
efficacy of antidepressants in older adults since 1994.60 Between 1996-2001, 97 studies
were conducted that evaluated antidepressant treatment in older adults; of these, 60 were
comparative studies (i.e., efficacy studies) and 37 were trials that were inactive-placebo
controlled trials.60 These clinical trials generally found antidepressants to be effective,
defined generally as a reduction in a depression score and/or remission of depression.
However, the participants in these clinical trials were not representative of the general
older adult population who most commonly receive these medications. Rather, the
participants in these trials had major depression and/or dysthymia, diagnoses that are both
defined by the DSM-IV; were primarily treated by specialists, such as psychiatrists,
rather than primary care physicians; or represented specialized populations of older
adults, such as in-patients, those in nursing homes or those with dementia. 60 Because
these studies primarily evaluated the effect of antidepressant medication on depression
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that met DSM-IV criteria, the effectiveness of antidepressants on depressive symptoms
that do not meet the DSM-IV threshold remains unclear.
A landmark study, the Sequenced Treatment Alternatives to Relieve Depression
(STAR*D), evaluated a system that would optimize the delivery of antidepressant
medication to outpatients in both a primary care setting as well as a psychiatric setting.61,
62

The goals of the study were to demonstrate that proper delivery of antidepressant

medication for depression in the “real-world” can be as nearly as effective as in clinical
trials.63 STAR*D was conducted in adults >55 years and operationalized remission as a
score <5 on the Quick inventory of depressive symptomology-self rate score and
improvement in mood was also measured by change in the Hamilton Depression Rating
Scale HDRS-17

64-66 67

The study was designed to evaluate a 4-tiered algorithm for

treating depression. Results from this study showed that the rate of remission was
approximately 30% in all patients receiving Citalopram, which was the first line therapy.
If the patient did not enter remission by 14-weeks, their medication was switched or
augmented, subsequently resulting in remission in an additional 30% of the remaining
subjects.64

Unlike many clinical trials, this study included adults with significant

comorbid medical and psychiatric problems, thus making the results applicable to a larger
population.65 One of the salient findings was that the majority of patients who were
treated with an antidepressants for 14-weeks with Citalopram did not have remission of
their depression.66, 67 By augmenting or changing the antidepressant medications each 14week step remission rates were about 33% after one step, 50% after two steps, 60% after
three steps, and 70% after four steps.61
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1.5.2. Clinical Trials in Primary Care
There are very few clinical trials examining antidepressant treatment in older
community-dwelling adults who are treated by their primary care physicians; yet, this
group comprises the majority of older adults who are prescribed antidepressants. A
systematic review in 2001 by Freudenstein et al. 68 identified only seven high quality
randomized controlled studies that evaluated the effectiveness of pharmacologic
treatment of depression in a primary care setting and included older adults from a
general, non-specialized population.68

Studies by Ekselius et al. and Patris et al.

compared two antidepressants, Citalopram vs. Sertraline and Citalopram vs. Fluoxetine,
respectively, in older adults with major depression in the primary care setting. 69, 70 Both
studies showed a reduction in the severity of depressive symptoms in each treatment
group as ascertained by the Montgomery-Asberg Depression Rating Scale, with no
difference between the antidepressant agents.69, 70 None of the studies in this systematic
review addressed the effectiveness of antidepressant treatment in older adults with
depressive symptoms not meeting DSM-IV criteria.
In addition to the studies identified by this systematic review, we identified a
randomized controlled trial that evaluated the effectiveness of antidepressant treatment in
older adults without major depression in a primary care setting.

Participants were

classified as depressed if they met DSM-IV criteria for dysthymia or had met modified
DSM-IV criteria for minor depression, meaning that they were required to have 4 weeks
of 2 to 3 symptoms rather than 2 weeks of 2 to 4 symptoms usually required for the
diagnosis. In this randomized controlled trial, participants treated with the antidepressant
medication Paroxetine showed moderate improvement of dysthymia and minor
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depression, as determined by comparing the mean reduction in the 20-item Hopkins
Symptom Checklist Scale in the treatment group with those who received placebo.71
A very recent meta-analysis72, which was not restricted to older adults, compared
the efficacy and acceptability of 12 major antidepressants (bupropion, citalopram,
duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, mirtazapine, paroxetine,
reboxetine, sertraline, and venlafaxine) among persons with major depression.
Escitalopram, mirtazapine, sertraline, and venlafaxine were significantly more efficacious
than the other antidepressants. Efficacy was defined as a reduction of at least 50% from
the baseline score on the Hamilton depression rating scale (HDRS) or Montgomery–
Asberg depression rating scale (MADRS), or who scored much improved or very much
improved on the clinical global impression (CGI) at 8 weeks.

Among the four

antidepressants that were found to be efficacious, sertraline and escitalopram were the
best tolerated.

1.5.3. Observational Studies in Primary Care
To the best of our knowledge, no studies have evaluated the efficacy or
effectiveness of antidepressants in older adults seen in primary care whose depressive
symptoms do not meet a DSM-IV threshold for depression, dysthymia or minor
depression. In the Personnes Agees Quid (PAQUID)73 study, a large representative
cohort of older community-dwelling older adults age > 65 in southwest France, the
researchers evaluated antidepressant use and depressive symptoms between 1988-1999.73
Whereas this study found that the prevalence of participants with depressive symptoms
decreased during the span of the study, while antidepressant use increased during the

11
same time period it did not determine whether antidepressants were associated with a
reduction in depressive symptoms.
In a longitudinal study, Blazer et al. 74 also attempted to determine the association
between antidepressant use and depressive symptoms. These investigators found no
association between antidepressant use and the overall burden of depressive symptoms.
However, the study was not designed to determine the effectiveness of antidepressant
medications, but did show that the CESD Scale scores were not significantly associated
with antidepressant use.
The effectiveness of antidepressants in a more natural or “real world setting” is
uncertain. The few available “real world” studies (i.e. studies that recruit participants
from the community and have more lax inclusion/exclusion criteria) have shown that
nearly 80% of older adults who are treated for their depression by their primary care
physician fail to improve or relapse back into depression by 6 months to 2 years.75-77

1.6. Questioning the Current Research on Antidepressant Efficacy
Much of the published research on antidepressant efficacy in adults, not limited to those
age 65 and older, have reported modest benefits. However, two recent meta-analyses,
which have evaluated the efficacy of antidepressants by combining published and
unpublished reports, have demonstrated that the efficacy of antidepressants is likely
overstated due to publication bias.78 Furthermore, a recent report by Turner et al.78,
comparing data from the Food and Drug Administration (FDA) to publications related to
antidepressant drug efficacy, found widespread discrepancies. Specifically, Turner et al.
78

identified 74 FDA registered studies that involved tests of antidepressant efficacy. They
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found that 31% of the studies were not published, involving 3449 study participants. Of
the 74 registered FDA studies with positive findings, 37 out of the 38 were published.
While out of 36 studies with negative findings, 22 were not published, 11 were published
in a misleading way that made them appear positive, and 3 were published in a way that
accurately reflected the negative results. Published studies suggested 94% of studies
were positive, whereas the FDA records showed that 51% were positive.
In a recent meta-analysis by Kirsch et al.79, when data from the FDA were
combined with those from published reports, the drug–placebo differences in
antidepressant efficacy increased as a function of baseline severity, but the benefits were
relatively small even for most severely depressed patients.79

1.7. Antidepressant Use and Transitions Between Depression States
Because depression is often a chronic condition with a remitting/relapsing
course,80,

81

preventing the next episode of depression is important. A meta-analysis

identified studies that evaluated the prognosis of depression and elevated depressive
symptoms in older adults (age >60). They identified 12 studies of the prognosis of
depression in elderly community and primary care populations. The combined results of
these studies indicated that 24 months after enrollment, 33% were well, 33% were
depressed, and 21% had died.77 In two years the prognosis of depression is poor in older
adults.
The remitting/relapsing nature of depression may be evaluated by taking into
consideration transitions between a depressed state and not depressed state. Recent
evidence from the PEP Study has indicated that transitions into and out of depression in
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older persons occur frequently over a 72-month period, a longer timeframe than has
previously been evaluated.82 Of the 269 participants (35.7%) who were depressed at
some point during the 72 months of follow-up, 48 (17.8%), 30 (11.2%), 17 (6.3%), and
12 (4.5%) were depressed during 2, 3, 4, and 5 consecutive time points, respectively.82
Based on prior analysis of the PEP data not all participants who were depressed remained
depressed and some participants who were not depressed transitioned to a depressed
state.

The study’s primary aim was to determine if there were gender differences

between those who transitioned into or out of depression. A transition from a depressed
state to a non-depressed state may be considered to be remission or recovery from
depression. Similarly, a transition from a non-depressed state to a depressed state may
represent relapse.
In the current study, we sought to evaluate the association between treatment with
antidepressant medications and changes in depressive symptoms over time in
community-dwelling older adults, thereby improving the “real-world” understanding of
how antidepressant medications impact depressive symptoms in this population.
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2. Specific Aims
Aim #1
To characterize depression and antidepressant use among older adults over time.

Aim #2A
To test the hypothesis that the use of antidepressant medications is associated with
a reduction in depressive symptoms in older adults over time.

Aim #2 B
To test the hypothesis that the likelihood of transitioning from a depressed state to
a non-depressed state will be higher among those taking antidepressant medications as
compared with those not taking antidepressant medications.
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3. Methods

3.1. Study Population
The study sample included the 754 participants of the Precipitating Events Project
(PEP), a prospective cohort study of nondisabled, community-living persons aged 70
years or older residing in New Haven County. 83 Enrollment occurred between March
1998 and October 1999, and participants were identified though a computerized listing of
3157 age-eligible members of a large health plan in New Haven, Connecticut. Potential
participants were mailed a letter that briefly described the study and explained that they
would be contacted by phone. During the phone interview, eligibility was assessed, and a
home visit was scheduled among consenting eligible persons. During the home visit,
eligibility was verified, informed consent was obtained, and a comprehensive baseline
assessment was completed.83
PEP was designed to evaluate the effect of precipitating events (e.g.,
hospitalization) on subsequent disability in older persons. Members were eligible if they
were community-living, English-speaking, and nondisabled (required no personal
assistance) in four key activities of daily living: bathing, walking across a room, dressing,
and transferring from a chair. Plan members were excluded based on three criteria:
diagnosis of a terminal illness with a life expectancy less than 12 months, plans to move
out of the New Haven area during the next 12 months, and significant cognitive
impairment with no available proxy.83 The participation rate was 75.2%. During the 7.5year follow-up period between March 1998, and January 2007, 279 participants died after
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a median of 54 months, and 32 dropped out of the study after a median of 27 months.
The Human Investigation Committee at Yale University approved the study.

3.2. Data Collection
Face-to-face in-home assessments were completed at baseline and every 18
months for up to 90 months (i.e., up to 6 possible assessments) by highly trained research
nurses using standard procedures. Each nurse was thoroughly trained and the interviews
were guided by the use of an assessment booklet that included all scripts to be read to the
participant followed by a prompt to the next question.
During the baseline assessment, data were collected on age, gender, race, and
educational level. During the baseline and each subsequent face-to-face assessment,
medical comorbidity was ascertained based on the presence of nine self-reported,
physician-diagnosed chronic conditions, including hypertension, myocardial infarction,
congestive heart failure, stroke, diabetes, hip fracture, arthritis, chronic lung disease, and
cancer. Cognitive status was assessed during each assessment using the Folstein MiniMental State Exam (MMSE), with scores ranging from 0 (lowest) to 30 (highest).84 Gait
speed was assessed by asking the participants to walk back and forth over a 10-foot (3-m)
course as quickly as possible. A timed score of greater than 10 seconds on the rapid gait
test indicated that the participant was physically frail.85 Deaths were identified and
confirmed by review of local obituaries and/or an informant.

3.2.1. Independent Variable: Antidepressant Use
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Use of antidepressant medications was ascertained directly by a one of the trained
nurse researchers. Participants were asked to retrieve all of their medications and were
reminded to check their purse and night table, etc. If a medication was not retrieved, the
nurse asked to see the participant’s medication list. If a list was unavailable, they were
asked to recall medications taken in the last two weeks. The nurse wrote down the name
of each of the medications on the data collection form and antidepressant medications
were subsequently coded based on the American Hospital Formulary system (AHFS)
code 28.16.04.
In the present study, antidepressants included the use of a Tricyclic antidepressant
(TCA), Selective Serotonin Reuptake Inhibitors (SSRI), or Non-SSRI/Non-TCA.
Trazodone was not considered an antidepressant because it is primarily prescribed as a
sleep aid.86 Similarly, Amitriptyline was not included as an antidepressant because it is
most commonly prescribed in older persons as a sleep aid or for pain at lower doses; and
data were not collected on medication dose or schedule.87-90
3.3. Primary Outcome Variable: Depression Change Score
Depressive symptoms were assessed during each of the six face-to-face
assessments (i.e., baseline, and 18, 36, 54, and 72 and 90 months) using the 11-item
Center for Epidemiological Studies-Depression scale (CESD).42, 43 The CESD asks about
symptoms that have occurred during the past week, such as “I did not feel like eating; my
appetite was poor” or “I enjoyed life”. Responses on each of the 11 items were scored 0 =
rarely or never, 1 = some of the time, or 2 = much or most of the time and were
subsequently summed to yield a total depressive symptoms score for each participant.
Scores were transformed to be compatible with the 20-item CESD91; hence, total scores
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ranged from 0 to 60, with higher scores indicating more depressive symptoms.
Depressive symptoms data were complete for 100% of the participants at baseline and
95%, 93%, 91%, 90% and 95% of the non-decedents at 18, 36, 54, 72 and 90 months,
respectively.
Change in depressive symptoms was determined for each 18-month interval by
calculating the difference in the CESD Scores between the two relevant time-points (i.e.
the baseline CESD score was subtracted from the 18-month CESD score.) A negative
change score indicated an improvement in symptoms while a positive change score
indicated a worsening of symptoms.
Table 1: CESD Depression Scale
Instruction to Participant:
I would now like to ask you a few questions are about how you have been feeling. For
each of the following statements, please tell me how often you have been feeling that
way during the past week.
Rarely Some of Much or REF
DK
or never the time most of
the time
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.

I felt that everything I did was an
effort – How often have you been
feeling this way?
I did not feel like eating; my
appetite was poor.
My sleep was restless.
I felt depressed.
I was happy.
I felt lonely.
People were unfriendly.
I enjoyed life.
I felt sad.
I felt that people disliked me.
I could not get “going”.

1

2

3

7

8

1

2

3

7

8

1
1
1
1
1
1
1
1
1

2
2
2
2
2
2
2
2
2

3
3
3
3
3
3
3
3
3

7
7
7
7
7
7
7
7
7

8
8
8
8
8
8
8
8
8
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3.4. Secondary Outcome Variable: Transitions into and out of Depressed/Not Depressed
States
Participants with CESD scores >20 were considered to be depressed. This cut
point has previously been shown to enhance the likelihood of detecting subsyndromal
depression among community-living older persons.92,93 Participants were classified as
depressed, non-depressed, or dead at each time-point. Transitions for the purpose of this
study was defined as passage from one state to another, also including the possibility that
they remain in the same state. Participants subsequently could have 6 possible transitions
from one time-point to the next: 1) depressed to not depressed; 2) depressed to depressed;
3) depressed to dead; 4) not depressed to depressed; 5) not depressed to not depressed; 6)
not depressed to dead. While evaluating the association between antidepressant use and
death was not a primary aim of the study, this transition needed to be included in order to
account for the significant source of missing data. The missing data in longitudinal
epidemiological studies on older adults is often death, and to assume they are missing at
random would bias the results.

3.5. Statistical Analysis for Univariate and Bivariate Findings
At each time-point, we determined the descriptive statistics f for the demographic
(age, race, gender and education level) and the clinical covariates (number of chronic
conditions, cognitive status score, physical frailty and depressive symptoms).

We

compared participant characteristics (demographic and clinical covariates) between those
with and without depression, and those who were and were not treated with an
antidepressant medication using

2

or t test statistics at each time-point.
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3.6. Change Score Model
3.6.1. Statistical Analysis for Change Score Model
We compared the depression change score between those who were and were not
treated with an antidepressant for each 18-month interval using general linear models.
Intervals refer to two time-points that are combined. The descriptive data such as age,
CESD score, MMSE, frailty and number of chronic conditions in each interval was from
the earlier time-point. For example, the data in Interval 2 would contain the descriptive
data would be from the 18-month interviews in addition to the change score and
transition data that will be described in the following paragraphs. Using intervals, we can
evaluate the association between antidepressant use at the beginning of each interval and
subsequent change in depressive symptoms from the beginning to the end of the interval.
The following figure illustrates how the time-points combined make up the intervals that
will be discussed.
Figure 1 :Illustration of time-points versus intervals

Three models were run to evaluate the association between antidepressant use and
change in depressive symptoms.

The first model was unadjusted, the second was
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adjusted for demographic features (age, race, gender and education), and the third was
adjusted for demographic such as: age (continuous), race (white vs. other), educational
level (continuous variable), and clinical covariates such as: number of chronic conditions
(continuous variable), frailty (yes vs. no) and cognitive status (continuous score).
We evaluated the longitudinal association between antidepressant use and
depression change score by using a repeated measures linear mixed model.

The

covariance structure was chosen by determining which model had the best fit by
comparing the Akaike's information criterion (AIC). The AIC allows us to determine the
goodness of fit of our estimated statistical model. The different model structures were
ranked according to their AIC and the final covariance structure chosen was the Toeplitz
model since it had the lowest AIC, thus providing the best fit.

3.7. Transition Models
3.7.1. Statistical Analysis for Transition Models
For each of the 18-month intervals, we calculated transition rates according to
whether (or not) participants were taking an antidepressant medication for the six
possible transitions, defined based on the three outcome states: non-depressed, depressed,
and death.

2

or Fisher exact statistics were used to evaluate the bivariate associations

between treatment and the six possible transitions for each time interval. To determine
whether the observed transitions were clinically meaningful, we calculated the percentage
of transitions that represented absolute changes in the CESD scores of 1 to 3 (small), 4 to
9 (moderate), 10 to 19 (large), and 20 or more (very large) points for each time interval.
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We evaluated the association between antidepressant use and the likelihood of the
6 possible transitions over time using longitudinal methods that optimized statistical
power. The first longitudinal model included participants who were not depressed at the
beginning of any 18-month interval, with participants who were not depressed during the
entire interval (i.e., at 2 consecutive 18-month time points) serving as the comparison
group. Specifically, we ran generalized multinomial logit models for nominal outcomes
that were estimated with a generalized estimating equation and used exchangeable
correlation structures. The second longitudinal model included participants who were
depressed at the beginning of any 18-month interval, with participants who were
depressed during the entire interval serving as the comparison group.
The magnitude of association was determined by odds ratios, which were adjusted
for age (continuous), race (white vs. other), educational level (continuous variable),
number of chronic conditions (continuous variable), frailty (yes vs. no) and cognitive
status (continuous score). Prior to running the fully adjusted model, an unadjusted model
was run and then a semi-adjusted model was run that controlled for demographic features
alone.

3.8. Sensitivity Analysis
To ensure that our results were robust, we performed two additional sets of
analyses. First, to address the possibility that participants who were depressed at baseline
might differ from those who subsequently developed depression, we re-ran the models
after excluding participants who were depressed at baseline. Second, we re-ran our
models after imputation for the small amount of missing data for the CESD score,
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MMSE, number of chronic conditions and frailty, collected during each of the 18 month
assessments. Multiple imputation was used with 50 draws per missing observation. The
imputations were conducted in a longitudinally sequential fashion. During imputation,
decedents were removed after death to ensure that their covariates were only informative
prior to death. This sequential imputation strategy retained the temporal order of the
longitudinal data and prevented incorrect inference due to potential bias of non-temporal
associations and effects of retaining descendents in the data imputation. All covariates
used in the main model were used to develop the model with the imputed data. In the
model using the imputed data, a categorical variable for MMSE, rather than a continuous
variable was used. Participants with an MMSE score of <=24 were categorized as having
cognitive impairment.

3.9. Power Calculation
Power calculations were performed using PASS software. For the linear model,
we did a post-hoc analysis and estimated power using an inequality test of two
proportions in a repeated measures design. For group sample sizes during interval 1 of 58
for those on an antidepressant and 679 not on an antidepressant, we achieved 100%
power to detect a difference in the CESD change score of 2.44-points in a design with 5
repeated measurements having a Toeplitz covariance structure when the standard
deviation is 0.27. For the transition model, we achieved 100% power using an inequality
test of two proportions in a repeated measure design. Approximately 650 participants
who have data at a minimum of 2 time-points. The power was estimated to detect an odds
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ratio of 2.0 thereby denoting at least a 100% increase in the rate of transitioning from
depressed to non-depressed (or from non-depressed to depressed).
All statistical tests were 2-tailed, and P<0.05 was considered statistically
significant. Analyses were performed used using SAS statistical software, version 9.194
and SAS-callable SUDAAN release 9.0.3.
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4. Results
4.1. Study Sample
The characteristics of the participants at each time point are provided in Table 1.
At baseline, the mean age was 78.4 years, and two-thirds of participants were women.
The average number of chronic conditions increased over time, from 1.75 at baseline to
2.34 at 90 months. Similarly, the proportion of frail participants increased from 43% at
baseline to 56% by 90 months.

Table 1: Characteristics of Participants Over The Course of 90 Months.
Baseline
18-mos
36-mos
54-mos
Characteristic
(n=754)
(n=675)
(n=612)
(n=538)
Age, yrs.; Mean
(SD)
Race, Non-white;
N (%)
Female; N (%)
Education, yrs;
Mean (SD)
No. of chronic
conditions;a
Mean (SD)
Cognitive status;b
Mean (SD)
Frailty; N(%)
Depression;c
N(%)

72-mos
(n=471)

90-mos
(n=419)

78.4 (5.3)

79.6 (5.1)

80.9 (5.1)

82.2 (4.9)

83.7 (4.8)

84.8 (4.7)

72 (9.6)

69 (9.8)

64 (10.0)

58 (10.3)

54 (10.8)

49 (11.1)

487 (64.6)

439 (65.0)

405 (66.2)

359 (66.7)

310 (65.8)

281 (67.1)

12 (2.9)

12 (2.9)

12 (2.8)

12 (2.9)

12.1 (2.8)

12 (2.8)

1.75 (1.2)

1.95 (1.3)

2.06 (1.3)

2.14 (1.3)

2.26 (1.3)

2.34 (1.3)

26.8 (2.5)

26.4 (2.9)

26.3 (3.4)

25.5 (3.9)

25.3 (4.7)

25.2 (4.8)

322 (42.7)

287 (42.5)

265 (43.3)

265 (49.4)

259 (55.0)

234 (56.1)

100 (13.3)

116 (17.2)

124 (20.3)

109 (20.3)

91 (19.1)

98 (23.4)

a. The 9 self-reported, physician-diagnosed chronic conditions included hypertension, myocardial
infarction, congestive heart failure, stroke, diabetes mellitus, hip fracture, arthritis, chronic lung
disease, and cancer (other than minor skin cancer).
b. As assessed by the Mini-Mental State Examination (MMSE).
c. CESD score >20
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4.2. Participants with Depressive Symptoms
A total of 100 participants (13.3%) were depressed (i.e., had a CESD score of
>20) at baseline. The proportion of participants who were depressed increased over time,
such that at 90-months 23% of participants were depressed. As indicated in Table 2, the
mean age and the proportion of non-white participants were similar for those with and
without depression at all time points. Participants with depression were more likely to be
women, have less education and report a higher number of chronic conditions.
Depressed participants were also nearly twice as likely to be frail as compared with nondepressed participants. Cognitive status was lower among depressed participants at each
time point, with the exception of the 54-month time-point.
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Table 2: Characteristics of Study Participants Over the Course of 90 Months According to Depression.
Baseline
18-mos
36-mos
Characteristic
(n=754)
(n=675)
(n=612)
Depressiona
Depressiona
Depressiona
YES
NO
pYES
NO
pYES
NO
(n=100)
(n=654) value
(n=116)
(n=559) value (n=124)
(n=488)
Age, y
78.6(5.4) 78.4(5.2) 0.79 80.4(5.42) 79.5 (5.0) 0.10 81.6(5.3) 80.7 (5.0)

pvalue
0.09

Female Sexb

86 (86.0)

401(61.3)

<.001

99 (85.3)

340(60.8)

<.001

102(82.3)

303(62.1)

<.001

Race, nonwhiteb
Education

14 (14.0)

58 (8.9)

0.10

10 (8.6)

56 (10.0)

0.65

14 (11.3)

48 (9.8)

0.63

11.1(2.7)

12.1 (2.9)

<.001

10.9 (2.8)

12.2 (2.8)

<.001

11.1 (2.6)

12.2 (2.8)

<.001

No. of
chronic
conditions
Cognitive
status
Frailty

2.08(1.4)

1.7 (1.2)

0.004

2.2 (1.32)

1.9 (1.2)

0.039

2.4 (1.4)

2.0 (1.2)

<.001

26.0(2.8)

26.9 (2.4)

0.002

25.4 (3.2)

26.6 (2.8)

<.001

25.4 (3.5)

26.5 (3.3)

0.002

62 (62.0)

260(39.8)

<.001

72 (62.1)

215(38.5)

<.001

84 (67.7)

181(37.1)

<.001

CESD score

24.8(4.8)

6.6 (6.1)

***

26.1 (6.5)

7.1(6.1)

***

24.9 (5.3)

7.3 (5.9)

***

pvalue
0.19

72-mos
(n=471)
Depressiona
YES
NO
(n=91)
(n=380)
84.3 (5.1) 83.6 (4.7)

pvalue
0.19

YES
(n=98)
85.3 (4.9)

NO
(n=321)
84.7 (4.6)

pvalue
0.25

<.001

74 (81.3)

236(62.1)

<.001

77 (78.6)

204(63.6)

<.001

42 (9.8)

0.52

8 (8.8)

40 (10.5)

0.62

10 (10.2)

38 (11.9)

0.64

12.2 (2.8)

<.001

11.2 (2.7)

12.3 (2.8)

<.001

11.1 (2.9)

12.3 (2.8)

<.001

No. of
chronic
conditions
Cognitive
status
Frailty

11.1
(2.8)
2.5 (1.5)

2.0 (1.2)

<.001

2.7 (1.3)

2.2 (1.3)

<.001

2.7 (1.3)

2.2 (1.3)

0.002

24.9
(4.3)
76 (69.7)

25.6 (3.8)

0.12

23.6 (5.6)

25.7 (4.3)

<.001

23.3 (6.0)

25.8 (4.3)

<.001

189(44.1)

<.001

65 (71.4)

194(51.1)

<.001

72 (73.5)

162(50.5)

<.001

CESD

26.1(5.9)

7.3 (6.1)

***

25.2(5.75)

8.4 (6.2)

***

26.3 (6.3)

8.2 (6.0)

***

Characteristic

Age, y
Female Sexb
Race,
nonwhiteb
Education

54-mos
(n=538)
Depressiona
YES
NO
(n=109)
(n=429)
82.7
82.0 (4.9)
(4.9)
96 (88.1) 263(61.3)
13 (11.9)

a. Depression is defined as a CESD score > 20.
b. Rate reported

90-mos
(n=419)
Depressiona
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4.3. Antidepressant Use
As shown in Figure 1, at any given time-point, approximately 10-15% of the
study population was taking an antidepressant medication. The proportion of participants
taking an antidepressant increased at each successive time-point, with the exception of 90
months where the rate approximated that of at 54-months.
Figure 1: Participants Taking an Antidepressant at Each Time-Point.
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Table 3 presents the breakdown of categories of antidepressants reported by the
study participants at each time-point.

At baseline, there were 40(69%) out of 58

antidepressant medications were for SSRI’s the remaining antidepressant medications
were TCA’s or Non-SSRI/Non-TCA antidepressants. At 90-months, 48 (72.2%) of the 66
antidepressant medications were SSRI’s and 14(21.2%) of the antidepressant medications
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were non-SSRI/non-TCA antidepressant medication. The decline in TCA antidepressant
medications from baseline to 90-months was 19.8%.

Table 3: Antidepressant Medications Ascertained at Each Time-Pointa
Baseline
18-mos
36-mos
54-mos
Antidepressants
N=58
N= 71
N= 82
N= 88
N (%)
N (%)
N (%)
N (%)
TCA’s
Desipramine
2 (3.4)
2 (2.8)
0 (0)
0 (0)
Doxepin
1 (1.7)
0 (0)
1 (1.2)
0 (0)
Imipramine
2 (3.4)
3 (4.2)
4 (4.9)
2 (2.3)
Nortriptyline
10 (17.0)
6 (8.5)
5 (6.1)
3 (3.4)
TCA %Total
15 (25.9) 11 (15.5) 10 (12.2)
5 (5.7)
SSRI’s
Citalopram
1 (1.7)
5 (7.0)
13 (15.9) 14 (15.9)
Escitalopram
0 (0)
0 (0)
0 (0)
3 (3.4)
Fluoxetine
8 (13.6)
12 (16.9) 10 (12.2) 11 (12.5)
Paroxetine
14 (23.7) 10 (14.1) 15 (18.3) 12 (13.6)
Sertraline
14 (23.7) 25 (35.2) 22 (26.8) 20 (22.7)
Serzone
3 (5.1)
1 (1.4)
0 (0)
1 (1.1)
SSRI %Total
40 (69.0) 53 (74.6) 60 (73.1) 61 (69.3)
Non-SSRI/Non-TCA
Bupropion
0 (0)
3 (4.2)
2 (2.4)
9 (10.2)
Duloxetine
0 (0)
0 (0)
0 (0)
0 (0)
Mirtazapine
0 (0)
2 (2.8)
6 (7.3)
7 (8.0)
Venlafaxine
3 (5.2)
2 (2.8)
4 (4.9)
6 (6.8)
Non-SSRI/Non-TCA
3 (5.2)
7 (9.9)
12 (14.6) 22 (25.0)
%Total

72-mos
N= 83
N (%)

90-mos
N= 66
N (%)

0 (0)
0 (0)
2 (2.4)
2 (2.4)
4 (4.8)

0 (0)
1 (1.5)
2 (3.0)
1 (1.5)
4 (6.1)

9 (10.8)
14 (16.9)
7 (8.4)
9 (10.8)
21 (25.3)
0 (0)
60 (72.3)

10 (15.2)
10 (15.2)
4 (6.1)
9 (13.6)
15 (22.7)
0 (0)
48 (72.7)

7 (8.4)
1 (1.2)
6 (7.2)
5 (6.0)
19 (22.9)

4 (6.1)
1 (1.5)
4 (6.1)
5 (7.6)
14 (21.2)

N= Reflects number of antidepressants and not number of participants because some participants
could be taking more than 1 antidepressant.

Table 4 presents the characteristics of the study population at each time point
according to antidepressant use. Age, race and education did not differ significantly
between those taking and not taking an antidepressant at any time point. Women were
more likely to be taking an antidepressant than men (p<0.05), although there was not a
significant gender difference at 72 or 90 months.

At 54-months and 72-months,
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participants taking an antidepressant were more likely to have a greater number of
chronic conditions than those not taking an antidepressant. At each time point, with the
exception of baseline, participants taking an antidepressant were more likely to have
lower cognitive scores as assessed by the MMSE (p<0.05). At most time-points except at
baseline and 18-months, participants taking an antidepressant were more likely to be frail
than those not taking an antidepressant (p<0.05).

In addition, those taking

antidepressants had a higher depressive symptoms score than those not taking an
antidepressant (p<0.05).
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Table 4: Characteristics of Study Participants Over 90 Months by Antidepressant Use.
Characteristic
Baseline
18-mos
36-mos
(n=754)
(n=675)
(n=612)
Antidepressanta
Antidepressanta
Antidepressanta
YES
NO
pYES
NO
pYES
NO
(n=58)
(n=679)
value
(n=68)
(n=594)
value
(n=76)
(n=532)
Age, y
77.8(5.3)
78.5(5.3)
0.26
79.3(4.9)
79.7(5.1)
0.36
80.7(5.4)
80.9(5.0)
Female Sex
56 (74.7) 431(63.5) 0.03
62 (76.5) 377(63.5) 0.03
59 (73.8) 346(65.0)
Race,non4 (6.9)
68 (9.8)
0.47
6 (8.8)
63 (9.8)
0.79
4 (5.3)
60 (10.6)
white
Education
12.0(2.5) 12.0 (2.9)
0.67
11.8(2.8)
12.0 (2.9)
0.30
12.0(2.7) 12.0 (2.9)
No.of chronic 1.92(1.2) 1.73 (1.2)
0.29
2.04(1.3)
1.93 (1.2)
0.55
2.06(1.3) 2.03 (1.3)
conditions
Cognitive
26.7(2.3) 26.8 (2.5)
0.71
25.7(3.7)
26.5 (2.8)
0.03
25.8(4.5) 26.3 (3.2)
status
Frailty
27 (46.6) 295(43.4) 0.54
35 (51.5) 258(43.4) 0.14
49 (64.5) 230(43.2)
Depressionc
17 (29.3)
83(12.2) <.001
27 (39.7)
89 (15.0) <.001
24 (31.6) 100(18.8)
CESD
15.1(9.2)
8.5 (8.3)
<.001 17.9(10.3) 9.5 (9.0)
<.001
16.0(9.1) 10.2 (9.0)
54-mos
72-mos
90-mos
(n=538)
(n=471)
(n=419)
Antidepressanta
Antidepressanta
Antidepressanta
YES
NO
pYES
NO
pYES
NO
(n=79)
(n=454)
value
(n=79)
(n=390)
value
(n=63)
(n=352)
Age, y
82.4(4.9) 82.1 (4.9)
0.90
84.0 (5.0) 83.7 (4.7)
0.60
84.8(4.7) 84.8 (4.6)
Female Sex
65 (77.4) 294(64.8) 0.01
63 (77.8) 247(63.3) 0.08
47 (70.1) 234(66.5)
Race,non7 (8.9)
51 (10.5)
0.65
6 (7.6)
48 (11.4)
0.32
7 (11.1)
42 (11.2)
white
Education
11.6(2.8) 12.1 (2.9)
0.12
11.9 (2.6) 12.1 (2.8)
0.69
12.0(2.7) 12.0 (2.9)
No.of chronic
2.1 (1.3)
2.1 (1.3)
0.02
2.59 (1.4) 2.19 (1.2)
0.01
2.5 (1.3)
2.3 (1.3)
conditions
Cognitive
24.3(5.4) 25.7 (3.5)
0.01
23.5 (6.4) 25.6 (4.2) 0.002
24.1(5.8) 25.4 (4.6)
status
Frailty
52 (65.8) 231(50.9) 0.004
57 (72.2) 221(56.7) 0.002
42 (66.7) 210(59.7)
Depressionc
35 (44.3)
74 (16.3) <.001
29 (36.7)
62 (15.9) <.001
22 (34.9)
76 (21.6)
CESD
17.6(10.5) 10.1 (9.1) <.001 16.6(10.1) 10.7 (8.5) <.001 16.8(10.9) 11.7 (9.5)
a.

b.
c.

See list of medications that qualified as antidepressants in Table 3.
Participants with a CESD score > 20.
Rate reported.

pvalue
0.51
0.03
0.14
0.35
0.16
0.03
<.001
0.001
<.001

pvalue
0.49
0.68
0.98
0.73
0.46
0.03
0.11
0.005
<.001
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Of the 100 participants with depression (i.e., CESD>20) at baseline, 17 (17%)
were taking an antidepressant. Between 17-31% of the depressed participants were
taking an antidepressant during the 90-month time period, as illustrated in Figure 2.
Figure 2: Participants with Depression Taking an Antidepressant.
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4.4. Depression Change Score at Each Interval
Table 5 presents the association between antidepressant use and the change in
depressive symptoms at each interval. In the unadjusted model, antidepressant use was
not associated with a change in the CESD score, with the exception of interval 2 where
antidepressant use was associated with an improvement in CESD score. These results did
not change after adjusting for the demographic features. However, after adjusting for the
demographic and clinical covariates, antidepressant use was associated with worsening of
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depressive symptoms for each interval except interval 2.

These associations were

statistically significant for intervals 1, 3 and 5.
Table 5: Association Between Antidepressant Use and Change in Depressive Symptoms
at Each Interval.
Estimate (ß)
Standard error
P-value
Unadjusted
Interval 1
0.16
1.08
0.88
Interval 2
-4.69
1.04
<0.001
Interval 3
0.86
1.18
0.47
Interval 4
-2.08
1.08
0.05
Interval 5
0.86
0.86
0.43
a
Adjusted for demographics
Interval 1
0.16
1.08
0.88
Interval 2
-4.71
1.05
<0.001
Interval 3
0.84
1.19
0.48
Interval 4
-2.01
1.08
0.07
Interval 5
0.75
1.08
0.49
a
b
Adjusted for demographics and clinical covariates
Interval 1
2.3
1.1
0.03
Interval 2
-1.3
0.99
0.19
Interval 3
2.7
1.1
0.02
Interval 4
1.1
1.0
0.29
Interval 5
2.5
1.0
0.01
Note: The Parameter estimate (i.e. ß) indicates the magnitude of change in depressive
symptoms, with a positive number indicating worsening of symptoms and a negative
number indicating an improvement of symptoms
a. Demographics= age, race, gender, education
b. Clinical Covariates = number of chronic conditions, MMSE score, frailty (y/n) and CESD
score at the beginning of each interval

4.5. Change Score/Mixed-effects Linear Longitudinal Regression
Table 6 presents the results from the final model evaluating the association
between antidepressant use and change in depressive symptoms over time. Overall,
antidepressant use was associated with an increase in depressive symptoms (i.e. the
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change in the CESD score worsened, on average, by 2.22 points).

However, this

association was not statistically significant.

Table 6: The Longitudinal Association Between Antidepressant Use and Change in
Depressive Symptoms by Mixed-Effects Linear Longitudinal Regression.
Fixed effects
Estimate (ß)
Standard error
P-value
Antidepressant use (yes)
2.22
0.99
0.14
Age (years)
0.01
0.02
0.81
Gender (female)
0.39
0.19
0.04
Education (years)
-0.06
0.04
0.08
Race (white)
0.57
0.29
0.05
CESD at beginning of each interval
-0.15
0.01
<0.001
Number of chronic conditions
0.34
0.07
<0.001
Frailty (yes)
0.04
0.25
0.88
MMSE (continuous score)
-0.13
0.04
<0.001
-2 Log-likelihood
17392.6
Akaike Information Criterion (AIC)
17402.6
ß: linear longitudinal regression coefficient, fixed effect: reflects the mean of the overall
criteria
P-value for the intercept is a solution from the fixed effects; all other p-values are from
the type 3 tests of fixed effects.

4.6. Transitions Rates at Each Interval
Table 7A presents transition rates not adjusted for covariates, according to
antidepressant use, for persons who transitioned from a depressed state to either a nondepressed state or remained depressed. At each time point, there was not a significant
association between antidepressant use and transitioning from a depressed state to a nondepressed state. Antidepressant use also was not associated with depressed participants
remaining depressed.
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Table 7A: Transition Rates Between the Three Outcome States Over Time According to Antidepressant Use.
Interval 1
Interval 2
Interval 3
Interval 4
Interval 5
Antidepressant
Antidepressant
Antidepressant
Antidepressant
Antidepressant Use
Use
Use
Use
Use
Transitions
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
(N=16)
(N=75) (N=25)
(N=84)
(N=23)
(N=96)
(N=33)
(N=70)
(N=28)
(N= 61)
Depressed
To
Nondepressed
N (%) 4 (25.0)
27 (36)
11(44) 30(35.7) 6 (26.1) 42(43.8) 10(30.3) 27(38.6) 10(35.7)
17(27.9)
p-value
0.46
0.50
0.12
0.42
0.49
To Depressed
N (%) 12(75.0) 40(53.3) 12(48) 42(50.0) 13(56.5) 42(43.8) 17(51.5) 35(50.0) 16(57.1)
37(60.7)
p-value
0.09
0.80
0.28
0.90
0.68
To Death
N (%)
0 (0)
8 (10.7) 2 (8.0) 12(14.3) 4 (17.4) 12(12.5) 6 (18.2) 8 (11.4)
2 ( 7.1)
7 (11.5)
p-value
0.18
0.40
0.54
0.36
0.51

As shown in Figure 3A, most transitions from a depressed state to a nondepressed state were based on moderate to large absolute changes in the CESD score (ie,
>10); small changes in the range of 1 to 3 points were observed for no more than 30% of
the transitions during any of the 18-month intervals.
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Figure 3A: The Absolute Change in CESD Scores For Participants that Transitioned from a
Depressed State to a Non-depressed State.
+D/+M CESD Change

+D/-M CESD Change
100%

100%

80%

80%

>20

60%

10-19
4-9

40%

>20

60%

10-19
4-9

40%

1-3

1-3

20%

20%

0%

0%

interval1 interval2 interval3 interval4 interval5

interval1 interval2 interval3 interval4 interval5

+D/-M: Those initially depressed and not taking an antidepressant medication
+D/+M: Those initially depressed and taking and antidepressant medication
The key refers to the absolute change in the CESD.

Table 7B presents transition rates not adjusted for covariates, according to
antidepressant use, for persons who transitioned from a non-depressed state to either a
depressed state or remained non-depressed. Among the non-depressed, antidepressant
use was associated with a higher likelihood of remaining non-depressed at each interval,
with the exception of interval 2. Participants who were initially not depressed and on an
antidepressant were more likely to transition to a depressed state for 2 of the 5 intervals.
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Table 7B: Transition Rates Between the Three Outcome States Over Time According to Antidepressant Use
Interval 1
Interval 2
Interval 3
Interval 4
Antidepressant Use
Antidepressant Use
Antidepressant Use
Antidepressant Use
Transitions
Yes
No
Yes
No
Yes
No
Yes
No
Nondepressed
(N=38)
(N=592)
(N=35)
(N=506)
(N=45)
(N=427)
(N=58)
(N=448)
To
Nondepressed
N (%)
28(73.7
500(84.5
30(85.7
412(81.4
28(62.2
349(81.7
40(69.0
388(86.6
)
)
)
)
)
)
)
)
p-value
0.04
0.51
0.01
<0.001
To Depressed
N (%)
7 (18.4)
57 (9.6)
3 (8.6)
64 (12.6)
10(22.2
41 (9.6)
9 (15.5)
29 (6.5)
)
p-value
0.10
0.36
0.01
0.002
To Death
N (%)
3 (7.9)
35 (5.9)
2 (5.7)
30 (5.9)
7 (15.6)
37 (8.7)
9 (15.5)
31 (6.9)
p-value
0.67
0.84
0.11
0.003

Interval 5
Antidepressant Use
Yes
No
(N=38)
(N=330)
24(63.2
)

268(81.2)
0.001

8 (21.1)

32 (9.7)
0.06

6 (15.8)

30 (9.1)
0.26

As shown in Figure 3B, most transitions from a non-depressed state to a
depressed state were based on moderate to large absolute changes in the CESD score (ie,
>10); small changes in the range of 1 to 3 points were observed for no more than 50% of
the transitions during any of the 18-month intervals.
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Figure 3B: The Absolute Change in CESD Scores For Participants that Transitioned from a Nondepressed State to a Depressed State.
ND/+M CESD Change

ND/-M CESD Change
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interval1 interval2 interval3 interval4 interval5

ND/-M: Those initially not depressed and not taking an antidepressant medication
ND/+M: Those initially not depressed and taking and antidepressant medication
The key refers to the absolute change in the CESD.

4.7. Generalized Estimating Equations Models
Table 8 presents the unadjusted and adjusted odds ratios from the longitudinal
models evaluating the association between antidepressant use and the likelihood of
transitioning between the three outcome states, among those who were depressed at the
beginning of each interval. Antidepressant use was not associated with a transition from
a depressed state to a non-depressed state over time, meaning that participants taking an
antidepressant were no more likely to transition to a non-depressed state than they were
to remain depressed, even after adjusting for demographics and the clinical covariates.
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Table 8: Association Between Antidepressant Use and Transitions Over the Course of 7.5
Years in Initially Depressed Participants.
Odds Ratio
95% CI
Unadjusted
Depressed
1
-Not Depressed
0.78
0.5-1.2
Dead
0.83
0.4-1.8
a
Adjusted for demographics
Depressed
1
-Not Depressed
0.80
0.5-1.3
Dead
0.90
0.4-2.0
a
b
Adjusted for demographics and clinical covariates
Depressed
1
-Not Depressed
0.85
0.5-1.4
Dead
0.49
0.2-1.2
Note: The Parameter estimate indicates the magnitude of change in depressive symptoms
and a positive number indicates worsening of symptoms, while a negative number indicates
an improvement of symptoms
a. Demographics= age, race, gender, education
b. Clinical Covariates = number of chronic conditions, MMSE score, frailty (y/n) and CESD
score at the beginning of each interval

Table 9 presents the unadjusted and adjusted odds ratios from the longitudinal
models evaluating the association between antidepressant use and the likelihood of
transitioning between the three outcome states, among those who were non-depressed at
the beginning of each interval. Results from the unadjusted model indicate that those
taking an antidepressant were more likely to transition from a non-depressed to a
depressed state, than to remain non-depressed (OR 2.01, 95% CI 1.3-3.0). This finding
persisted after adjustment for demographic (OR 1.9, 95% CI 1.2-2.9) and clinical
covariates (OR 1.79, 95% CI 1.2-2.8).
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Table 9: Association Between Antidepressant Use and Transitions Over the Course of
7.5 Years in Initially Non-depressed Participants.
Odds Ratio
95% CI
Unadjusted
Not Depressed
1
-Depressed
2.01
1.3-3.0
Dead
2.29
1.4-3.7
Adjusted for demographics
Not Depressed
1
-Depressed
1.90
1.2-2.9
Dead
2.46
1.5-4.0
Adjusted for demographics and clinical covariates
Not Depressed
1
-Depressed
1.79
1.2-2.8
Dead
1.80
1.1-3.0
Note: The Parameter estimate indicates the magnitude of change in depressive
symptoms and a positive number indicates worsening of symptoms, while a negative
number indicates an improvement of symptoms
a. Demographics= age, race, gender, education
b. Clinical Covariates = number of chronic diseases, MMSE score, frailty (y/n) and CESD
score at the beginning of each interval

4.8. Sensitivity Analysis
4.8.1. Eliminating Participants Who Were Depressed at Baseline
Table 10 indicates that when participants with elevated depressive symptoms at
baseline were omitted from the analysis, use of an antidepressant medication was still not
associated with a change in depression scores.
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Table 10 : The Longitudinal Association Between Antidepressant Use and Change in
Depressive Symptoms by Mixed-Effects Linear Longitudinal Regression, Excluding
Participants Who Were Depressed at Baseline.
Fixed effects
Estimate (ß)
Standard error
P-value
Antidepressant use (yes)
1.30
1.06
0.21
Age (years)
0.0006
0.02
0.98
Gender (female)
0.35
0.19
0.08
Education (years)
-0.06
0.04
0.12
Race (white)
0.44
0.32
0.17
CESD at beginning of each interval
-0.16
0.01
<0.001
Number of chronic conditions
0.34
0.08
<0.001
Frailty (yes)
0.05
0.27
0.87
MMSE (continuous score)
-0.13
0.04
0.002
-2 Log-likelihood
15210.7
Akaike Information Criterion (AIC)
15220.7
ß: linear longitudinal regression coefficient, fixed effect: reflects the mean of the overall
criteria
P-value for the intercept is a solution from the fixed effects; all other p-values are from
the type 3 tests of fixed effects.
As shown in Table 11, for participants who started an interval in a depressed state,
antidepressant use was not associated with the transition from depression to a nondepressed state. These findings persisted after adjusting for demographic and clinical
covariates.
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Table 11: Association Between Antidepressant Use and Change in Depressive
Symptoms at Each Interval, in Initially Depressed Participants; Omitting Participants
Who Were Depressed at Baseline.
Odds Ratio
95% CI
Unadjusted
Depressed
1
-Not Depressed
0.77
0.4-1.5
Dead
0.71
0.2-2.2
Adjusted for demographics
Depressed
1
-Not Depressed
0.84
0.4-1.7
Dead
0.87
0.3-3.0
Adjusted for demographics and clinical covariates
Depressed
1
-Not Depressed
0.57
0.4-1.7
Dead
0.49
0.1-1.9
The results are from 4 intervals since we eliminated participants who had depression at
baseline
Note: The Parameter estimate indicates the magnitude of change in depressive
symptoms and a positive number indicates worsening of symptoms, while a negative
number indicates an improvement of symptoms
a. Demographics= age, race, gender, education
b. Clinical Covariates = number of chronic diseases, MMSE score, frailty (y/n) and CESD
score at the beginning of each interval
Table 12 provides the results of the generalized estimating equation (GEE) model
evaluating participants who were not depressed at baseline. Similar to the GEE results
from the original models, participants taking an antidepressant were more likely to
transition from a non-depressed state to a depressed state rather than to stay nondepressed. This finding persisted after adjustment for the demographic and the clinical
covariates (OR=2.43, 95% CI 1.3-4.5).
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Table 12: Association Between Antidepressant Use and Change in Depressive
Symptoms at Each Interval, in Initially Not Depressed Participants; Omitting
Participants Who Were Depressed at Baseline.
Odds Ratio
95% CI
Unadjusted
Not Depressed
1
-Depressed
2.60
1.5-4.6
Dead
2.82
1.6-5.1
Adjusted for demographics
Not Depressed
1
-Depressed
2.51
1.4-4.5
Dead
2.96
1.6-5.4
Adjusted for demographics and clinical covariates
Not Depressed
1
-Depressed
2.43
1.3-4.5
Dead
2.19
1.1-4.3
Note: The Parameter estimate indicates the magnitude of change in depressive
symptoms and a positive number indicates worsening of symptoms, while a negative
number indicates an improvement of symptoms
a. Demographics= age, race, gender, education
b. Clinical Covariates = number of chronic diseases, MMSE score, frailty (y/n) and CESD
score at the beginning of each interval
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4.8.2. Imputed Data
The results did not change appreciably after imputation for missing data. Using
imputed data for the CESD at the beginning of each interval, number of chronic
conditions, frailty and cognitive status as shown in Table 13, antidepressant use was not
associated with change in depressive symptoms over time (ß=2.44; SE 0.91; p=0.08).

Table 13: The Longitudinal Association Between Antidepressant Use and Change in
Depressive Symptoms by Mixed-Effects Linear Longitudinal Regression, Imputed Data
Results.
Fixed effects
Estimate (ß)
Standard error
P-value
Antidepressant use (yes)
2.44
0.91
0.08
Age (years)
-0.07
0.02
0.73
Gender (female)
0.23
0.18
0.22
Education (years)
-0.07
0.03
0.04
Race (white)
0.59
0.28
0.04
CESD at beginning of each interval*
-0.15
0.01
<0.001
Number of chronic conditions*
0.29
0.07
<0.001
Frailty (yes)*
0.43
0.22
0.04
MMSE (no cognitive deficit)*
0.85
0.30
0.004
-2 Log-likelihood
18435.7
Akaike Information Criterion (AIC)
18445.7
ß: linear longitudinal regression coefficient, fixed effect: reflects the mean of the overall
criteria
P-value for the intercept is a solution from the fixed effects; all other p-values are from
the type 3 tests of fixed effects.
*imputed variables

Similarly, antidepressant use was not associated with a transition from a
depressed state to a non-depressed state, over time, among those participants who were
depressed at the beginning of each interval (Table 14); but as shown in Table 15
antidepressant use was associated with a transition from a non-depressed state to a
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depressed state, over time, among those participants who were non-depressed at the
beginning of each interval (OR 1.80, 95% CI 1.2-2.8).

Table 14: Association Between Antidepressant Use and Change in Depressive Symptoms at Each
Interval, in Initially Depressed Participants, Imputed Data Results.
Odds Ratio
95% CI
Unadjusted
Depressed
1
-Not Depressed
0.78
0.5-1.2
Dead
0.84
0.4-1.8
Adjusted for demographics
Depressed
1
-Not Depressed
0.82
0.5-1.3
Dead
0.93
0.4-1.4
Adjusted for demographics and clinical covariates
Depressed
1
-Not Depressed
0.79
0.5-1.2
Dead
0.70
0.3-1.6
Note: The Parameter estimate indicates the magnitude of change in depressive symptoms and a
positive number indicates worsening of symptoms, while a negative number indicates an
improvement of symptoms
a. Demographics= age, race, gender, education
b. Clinical Covariates = number of chronic diseases, MMSE score, frailty (y/n) and CESD score at
the beginning of each interval
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Table 15: Association Between Antidepressant Use and Change in Depressive Symptoms at Each
Interval, in Initially Not Depressed Participants, Imputed Data Results.
Odds Ratio
95% CI
Unadjusted
Not Depressed
1
-Depressed
2.02
1.3-3.0
Dead
2.30
1.4-3.7
Adjusted for demographics
Not Depressed
1
-Depressed
1.88
1.2-2.9
Dead
2.33
1.4-3.8
Adjusted for demographics and clinical covariates
Not Depressed
1
-Depressed
1.80
1.2-2.8
Dead
1.93
1.2-3.1
Note: The Parameter estimate indicates the magnitude of change in depressive symptoms and a
positive number indicates worsening of symptoms, while a negative number indicates an
improvement of symptoms
a. Demographics= age, race, gender, education
b. Clinical Covariates = number of chronic diseases, MMSE score, frailty (y/n) and CESD score at
the beginning of each interval
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5. Discussion

The treatment of depression and depressive symptoms in the older adult consists
almost entirely of antidepressant medications prescribed in primary care settings.
However, there is relatively little information on the efficacy or effectiveness of
antidepressant medications on depressive symptoms in the community. Therefore, this
longitudinal study of older adults in New Haven county sought to describe the use of
antidepressant medications over time, to evaluate the association between antidepressant
use and reduction in the severity of depressive symptoms over time, and to determine if
antidepressant use was associated with transitioning from a depressed state to a nondepressed state.

We found that most participants with depression were not taking

antidepressant medications. Furthermore, antidepressant use was not associated with a
reduction in the severity of depressive symptoms over time; nor was it associated with
transitioning from a depressed state to a non-depressed state.

5.1. Potential Underdiagnosis and/or Undertreatment of Depression
During the 90-month follow-up, between 13% to 23% of the study participants
had elevated depressive symptoms. These prevalence rates are slightly higher than the
rates of 6% to 18% that have previously been reported in the literature.2-6 Reasons for
this may include the higher mean age and more diverse racial composition of our sample
compared with the samples in these other studies.95 Furthermore, the PEP study oversampled participants who were physically frail. As prior studies have indicated that
frailty is associated with depression, the higher prevalence of frailty in our study
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population, as compared with other populations of community-dwelling older persons,
may account for the higher rates of elevated depressive symptoms reported in our study.17,
96

5.2. Potential Undertreatment
At all time-points during the 90-month follow-up, more than 60% of participants
with elevated depressive symptoms were not taking an antidepressant. Prior studies have
indicated that depression in older adults is undertreated, such that, at most, no more than
a third to half of patients who have been identified as depressed are treated by a physician
by either/or pharmacological or non-pharmacological methods..30,

47, 48,97-99

Studies

evaluating antidepressant use in older adults with depression have reported rates ranging
from 19% to 42%.97-99 However, what we know about rates of antidepressant medication
treatment primarily comes from studies of older adults with a clinical diagnosis of
depression.

In addition, with the exception of one study, 100 the published studies

evaluating antidepressant use in older persons have been cross-sectional.97-99

For

example, Skoog et al. evaluated antidepressant medication treatment before the
widespread use of SSRI’s and found that 19% of older adults with depressive disorders
and 24% of those with major depression were taking antidepressant medications. 97
Consequently, relatively little in known about the rates of antidepressant use in depressed
older persons over time.
In the Longitudinal Aging Study Amsterdam (LASA)101, antidepressant use was
examined over 10 years, from 1992 to 2002, in a representative, community-based
population of persons aged 55-85 years. The rate of antidepressant use ranged from 2%
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to 5.3%. As in our study, antidepressant use increased over time in the population as a
whole, and in the subgroups who had a depressive disorder. For example, the rate of
antidepressant use increased from 2.9% to 12.1% among participants who had elevated
depressive symptoms, defined as CESD >16, and from 15% to 30.4% among those who
were clinically depressed.
Our study differs from the LASA study in a several ways. First, our study was
conducted between 1998-2007, a period during which SSRI’s were first-line therapy for
depression. This is important because the rates of antidepressant use have increased since
the introduction of SSRI’s. Second, the LASA study population, which included only
Dutch participants living in the Netherlands, was much more homogeneous than our
population . Thus, the results may not generally applicable to a population in the United
States. Third, the LASA study interviewed participants every 3 years for 12 years (4
time-points) , while we interviewed participants every 18 months for 7 ½ years (6 total
time-points). At 90 months, however, there was a slight decline such that less than 25%
of participants with elevated depressive symptoms were taking an antidepressant (see
Figure 2 in results). Because we only have one time-point that demonstrates a decline in
the rates of antidepressant use, it is difficult to infer the cause. However, this finding
raises the question as to whether under treatment and under recognition of depression
may occur more frequently in the old-old as compared with the young-old.
Depressive symptoms may go untreated because they are not recognized. Major
depression goes unrecognized or underdiagnosed in approximately 60% of the older
patients seen in primary care settings.102,

103

In all adults major depression was

unrecognized in 44% of patients, those with symptoms that were less severe were more
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likely to have unrecognized depression.104 While in the old-old (age>85) depression was
unrecognized in 75% of the patients by a primary care physician. 105 In hospitalized
geriatric patients, psychogeriatricians were able to identify 43% of cases of depression
while the geriatricians only identified 19% of the cases.106 Depression and depressive
symptoms are missed in more then half of patient’s in a variety of settings. Physicians
may be better able to identify patients with greater degrees of depression, thus not
identifying the majority of patients with elevated depressive symptoms who still may
benefit from treatment.107-109 While undertreatment of depression may be attributable to
underrecognition of depression, we could not address this issue directly in the current
study since we did not have access to medical records. Nonetheless, increased detection
of depressive symptoms would likely lead to enhanced treatment of this disabling
disorder, with potential benefits in quality of life and other health outcomes.
There have been some initiatives to increase screening of depressive symptoms in
older adults by primary care physicians. In one study, primary care physicians were
provided with information about diagnosing and treating depression in older adults.75
Despite the increased detection and awareness of depression, this intervention did not
lead to significant improvement of the patients.75
Overall, our findings highlight potential opportunities to enhance the
identification of depression and to optimize medical treatment of depression among older
adults.

5.3. Effectiveness of Antidepressants
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Contrary to our hypothesis, we found that antidepressant use was not associated
with a reduction in the severity of depressive symptoms. In fact, on average, depressive
symptoms worsened among participants taking antidepressant medications.

The

consistency of our findings over 4 of the 5 different time intervals provides strong
evidence that antidepressant use, as prescribed in clinical practice, is not associated with
an improvement in depressive symptoms.
As noted in the Introduction, what we know about the effectiveness of
antidepressant medications in older persons primarily comes from clinical trials that have
included specialized populations such as those being treated in an in-patient setting, those
being treated by a psychiatrist, or those who have been diagnosed with a clinical
depressive disorder. Consequently, treatment recommendations are extrapolated from
findings that may not be generalizable to the majority of older adults who have
depressive symptoms .
We also evaluated transitions into and out of depression states at 18-month
intervals for 7 1/2 . years, using longitudinal methods that enhanced our power to detect
clinically meaningful differences. We found that antidepressant use was not associated
with the transition from a depressed state to a non-depressed state. It has been estimated
that only 40 to 65% of all adults, including older adults, have a favorable response to any
given antidepressant.110 In 4 out of the 5 time intervals, we found that less than 40% of
the participants who were depressed and taking an antidepressant medication transitioned
to a non-depressed state. In contrast, we found that non-depressed persons who were
taking an antidepressant were more likely to transition to a depressed state.

52
There are several possible reasons why depressive symptoms did not improve
despite treatment with an antidepressant. First, possible lack of adherence to the medical
treatment is possible. Second, the dose of the antidepressant medications may have been
too low.

Third, the treatment duration may not have been long enough. Fourth,

physicians may have prescribed antidepressant medication to patient’s who were sicker.
It is possible that we found a worsening of depressive symptoms because there
could have been a high degree of non-adherence.111 Some variables that have been
identified as being related to poor adherence include poorer social support 112, less nonfamily interaction, greater basic and instrumental activities of daily living limitations,
poor self-rated health, higher baseline depression scores.113 Of older persons who receive
a prescription for an antidepressant, less than half fill the prescription.29 Given the high
prevalence of non-adherence, it is important to have a follow-up period within a couple
of weeks to determine if the patient started the medication and if they are tolerating the
medication.29, 36
It is also possible that primary care physicians did not achieve a therapeutic dose
of the antidepressant medication. In a survey of primary care physicians in Ontario,
Canada it was found many physicians were not willing to titrate the dose of their
prescribed antidepressant medications beyond the lower half of the therapeutic range
even when patients were tolerating the medications without side effects but were not
responding to treatment.114, 115 Another study found that only 56% of study participants
were on an adequate dose of antidepressants.115
It is possible the treatment was sub-optimal in duration. Our 18-month timeperiod would have allowed enough time for the antidepressant to take effect; however
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participants may not have been taking an antidepressant during the entire interview
interval. Up to 12 weeks of treatment with antidepressant medications may be needed to
elicit a full response and remission.110,

116, 117

There is evidence indicating that

improvement of symptoms of minor depression can occur independent of treatment,
which is why one of the recommendations for treating minor depression is watchful
waiting.118, 119 However it is possible that physicians may not re-address the depressive
symptoms, or that the patient does not follow-up in the recommended amount of time.
Once therapy is initiated it may likely be sub-optimal in duration.
The observed worsening of depressive symptoms in participants on an
antidepressant may be due to confounding by indication.

Possible indications for

antidepressant use can be a diagnosis of depression or related psychiatric disorders and
depression severity. It may be that physicians readily identified those patients who had a
past medical history of depression or a high degree of depressive symptoms. However,
we controlled for the CESD score at the beginning of each interval for both the change
score model and the transitions model. Indication bias can be controlled for by adjusting
for a past history of depressive disorders and whether the patient had been on
antidepressants in the past.

5.4. The Future for Depression Treatment in Older Adults
While under recognition of depression in older adults continues to be a problem,
there are new healthcare models that may promote the delivery of better mental health
care to this population.

Studies have shown that collaborative care models that

incorporate mental health specialty treatment into primary care settings, such as those
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used in the Veterans’ Affairs Primary Care, IMPACT and PROSPECT studies, result in
significant improvements in depression outcomes for older primary care patients.120-122
The Improving Mood Promoting Access to Collaborative Treatment (IMPACT)
randomized those with major depression or dysthymia to usual primary care treatment or
a collaborative treatment group (e.g. participants were assigned a case manager in
addition to their medication and/or counseling).

It was found that the patient’s

randomized to the collaborative treatment group had better outcomes and had lower
health care costs.121, 122 The Prevention of Suicide in Primary Care Elderly-Collaborative
Trial study (PROSPECT) a specially trained master’s level health specialist works with
the primary care physician to identify and suggest treatments for depression in older
patients, with a goal of increasing adherence to pharmacological treatment. 123-125 The goal
of this study was to create a model that would reduce suicide in older adults and may be
implemented in a primary care medical practices.

Suicidal ideation was reduced

regardless of depression severity in patients that participated in the PROSPECT trial.126
In 2007, an expert panel convened and strongly recommended that depression
care management-modeled interventions be provided in primary care clinics.127 There is
strong evidence that the collaborative care models described above are effective. Future
studies may want to include more training for physicians with respect to appropriate
dosing and drug selection, more frequent and objective follow-up assessments, and the
use of non-pharmacological (i.e. psychotherapy) treatment.. In addition, many of the
studies described above were conducted in academic centers or clinics closely linked to
an academic center, future studies would want to evaluate feasibility in a non-academic
environment where resources may be limited.
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5.5. Study Limitations
Some limitations of the study should be considered when interpreting the results.
First, we did not have information about dosage, frequency, duration or changes in
medication. However, we had information on who was taking an antidepressant at every
18-month time-point. Also, we had no information about adherence to medications.
Future studies evaluating antidepressant effectiveness in older adults should include
specific information about the antidepressant medication, dosage and adherence. This
information would allow us to further categorize participants as having aggressive
treatment, adequate treatment, or undertreatment of their depression.

Because

information regarding participants’ depression status before the baseline interview was
not available, we could not determine if participants’ first transition from a non-depressed
to a depressed state represents incident depression. We also do not know if a participant
had major depression in the past.

Consequently, it is possible that the depressed

participants in our study that are not being treated have treatment resistant depression or
depression that is not fully remitted. However, to control for this, we ran sensitivity
analysis that excluded subjects who were depressed at baseline and obtained the same
results. 29-31
We also did not assess non-pharmacologic treatments of depression. Hence, our
rates for depressant treatment may have been underestimates. However, very few older
adults see a psychotherapist for their depression and this likely would not affect a large
proportion of our participants. Future studies should include measures to assess these
variables.
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Because our assessments were completed every 18-months, it is possible that
some participants were treated for depression between two time time-points and achieved
remission before the next assessment. If brief treatments and remissions occurred at
random with respect to the assessment intervals, we should have observed many of them,
but would have underestimated the rate and effectiveness of the antidepressant treatment.
Future studies would want to decrease the duration between interviews to 6-months to 1
year.
Because our study participants were members of a single health plan, initially
nondisabled, and at least aged 70 years at baseline, the generalizability of our findings to
other older adult populations may be questioned.

However, the demographic

characteristics of our study population, including years of education, closely mirror those
of persons 70 years or older in New Haven County, Connecticut, which, in turn, are
comparable to those in the United States as a whole, with the exception of race. New
Haven County has more non- Hispanic whites in this age group than in the United States
(91% versus 84%). Furthermore, generalizability depends not only on the characteristics
of the study population but also on its stability over time. The high participation rate,
completeness of data collection, and low rate of attrition for reasons other than death all
enhance the generalizability of our findings and at least partially offset the absence of a
population-based sample.
Finally, this was an epidemiologic study and not a clinical trial so inferences
about treatment effectiveness must be made cautiously. Again, an unexpected finding
was that antidepressant treatment was not associated with improvement of depressive
symptoms, but was associated with worsening of depressive symptoms.
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5.6. Conclusions and Recommendations
Our findings raise concerns about the effectiveness of antidepressant medications,
as prescribed to older adults in clinical practice. The results of this study indicate that
more research is needed to understand the role of antidepressant medications in older
adults with elevated depressive symptoms.
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